Ocimum Biosolutions Biotracker™ LIMS selected as M. D. Anderson standard for core facility automation

Printer-friendly versionPDF version

Ocimum's Biotracker™ LIMS solution has been selected by The University of Texas M. D. Anderson Cancer Center as their standard for the automation of their Research Core Facilities. The first core facility to be automated shall be the Genomics Core Facility.

Hyderabad, Andhra Pradesh, India, March 19, 2010: Ocimum Biosolutions, a leading provider of Life Sciences Laboratory Information Management Systems (LIMS) and genomic solutions, is pleased to announce that its Biotracker™ LIMS solution has been selected by The University of Texas M. D. Anderson Cancer Center as their standard for the automation of their Research Core Facilities. The first core facility to be automated shall be the Genomics Core Facility.

M. D. Anderson supports a wide range of ongoing research initiatives and labs. It required a LIMS system that was robust enough to support the multiple lab environments and technologies in use today with the flexibility to handle the emerging technologies of tomorrow. M. D. Anderson also required a solution that could integrate to a variety of systems and databases in use today at the institution.

The Biotracker™ LIMS solution’s value-added, out-of-the-box capabilities, its flexibility and extensibility and its fully functional Application Programming Interface (API) satisfied M. D. Anderson’s requirements.

“It was critical to us that the laboratory automation solution chosen for M. D. Anderson’s broad range of laboratories be able to handle all our needs from a single solution platform that fits into our enterprise architecture,” said Krishna Sankhavaram, Director of Research Information Systems, M. D. Anderson. “Ocimum Biosolutions’ Biotracker™ LIMS will support all our labs and integrate this system into our services-based application environment while minimizing our IT footprint and internal support costs,” continued Mr. Sankhavaram.

The first scheduled implementation will be addressing both short term (integrity of data, managing genomic expression experiments and automation) and long term (scalability) goals for the Genomics Core Facility. The extensive configurability, exhaustive search capability and wide array of reports that will be provided as a part of this implementation will enable the core facility to automate inventory tracking, support high throughput processing of samples, and facilitate easy analysis of QC data.

“We at Ocimum are ecstatic that M. D. Anderson, which is recognized as one of the premier cancer research centers globally, has selected Biotracker™ LIMS as their standard LIMS solution,” said Anu Acharya, CEO of Ocimum Biosolutions. “We look forward to a long term relationship whereby both parties will benefit from our interactions.”

About Biotracker™
Biotracker™ is a specialty Lab Information Management Solution (LIMS) for enhancing productivity and effectiveness in life sciences research laboratories. Biotracker™ addresses the challenges of supporting multi-disciplinary labs, collaboration and data management needs. Biotracker™ offers several specialty modules that address the needs in life sciences research laboratories performing Biobanking, Gene Expression, Genotyping, DNA Sequencing, and Proteomics. For more details, please visit www.lims.ocimumbio.com.

About Ocimum Biosolutions
Ocimum Biosolutions is a global integrated genomics services company with over 250 employees in Hyderabad, India; Gaithersburg, MD in US; and The Netherlands. Ocimum provides comprehensive genomic reference databases, life science lab information management solutions, GLP-compliant microarray services and essential research consumables. Over two thirds of the top 25 pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred outsourcing partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers.
Our global infrastructure, standardized procedures, capacity, expertise and highly skilled staff support drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. In creating the world's largest commercial gene expression databases – BioExpress® and ToxExpress®, we have developed expertise and capabilities that are unparalleled in the genomic services industry. Ocimum has been consistently ranked as India’s fastest growing biotechnology company and one of the fastest growing technology companies over the last four years by Deloitte Touche Tohmatsu.
For more information, please visit www.ocimumbio.com

About M. D. Anderson
The University of Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. M. D. Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For six of the past eight years, including 2009, M. D. Anderson has ranked No. 1 in cancer care in “America's Best Hospitals,” a survey published annually in U.S. News & World Report.